ReviewAutoimmunity2008
Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: advantages and disadvantages.
Review in Autoimmunity, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 18 citations in OpenAlex.
- Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I.Bone marrow transplantation · 2011Trial
- High-dose Cyclophosphamide Without Stem Cell Rescue in Autoimmune Diseases: A Systematic Review.European journal of rheumatology · 2024Review
- Improved Behavior and Neuropsychological Function in Children With ROHHAD After High-Dose Cyclophosphamide.Pediatrics · 2016Article
- Hematopoietic stem cell transplantation for systemic lupus erythematosus.Clinical & developmental immunology · 2012Review
- High-dose cyclophosphamide without stem cell rescue for the treatment of refractory Behcet's disease.Seminars in arthritis and rheumatism · 2011Article
- Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
- Cyclophosphamide for rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome.The Journal of pediatrics · 2011Article
- High-dose cyclophosphamide for autoimmunity and alloimmunity.Immunologic research · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Hematopoietic stem cell transplantation (HSCT) for the treatment of severe autoimmune disorders continues to show great promise. The morbidity and mortality of the approach is relatively low and clinical benefit has been demonstrated in many, but not all patients. Furthermore, relapse following HSCT is not uncommon. Most centers now prefer nonmyeloablative conditioning regimens using high dose cyclophosphamide prior to SCT; however, emerging data show that high dose cylophosphamide can be administered safely without the need for HSCT. Eliminating the use of HSCT after high dose cyclophosphamide shortens the duration of the procedure by several weeks, markedly reduces the cost of the procedure and eliminates the potential of reinfusing autoreactive lymphoctes with the autograft.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.